Literature DB >> 28223765

Increased Serum High Mobility Group Box 1 (HMGB1) Concentration and the Altered Expression of HMGB1 and Its Receptor Advanced Glycation Endproducts in Pemphigus.

Jia-Yi Li1, Yong-Hong Lu1, Li-Wen Zhang1, Pei-Mei Zhou1, Tao Chen1.   

Abstract

Entities:  

Year:  2017        PMID： 28223765      PMCID： PMC5318513          DOI： 10.5021/ad.2017.29.1.121

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  4 in total

Review 1.  Apoptotic pathways in the pathogenesis of pemphigus: targets for new therapies.

Authors:  Roberta Lotti; Alessandra Marconi; Carlo Pincelli
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

2.  Pemphigus vulgaris: accumulation of apoptotic cells in dermis and epidermis possibly relates to pathophysiology through TNF-alpha production by phagocytes.

Authors:  Mariana Chiapa-Labastida; Alejandro Zentella-Dehesa; Gladys León-Dorantes; Ingeborg Becker
Journal:  Eur J Dermatol       Date:  2011 Nov-Dec       Impact factor: 3.328

Review 3.  HMGB1 is a therapeutic target for sterile inflammation and infection.

Authors:  Ulf Andersson; Kevin J Tracey
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

4.  Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris.

Authors:  Tao Chen; Zai-pei Guo; Li Li; Ling Wang; Rui-zhen Jia; Na Cao; Sha Qin; Meng-meng Li
Journal:  Arch Dermatol Res       Date:  2013-02-26       Impact factor: 3.017
  4 in total
  1 in total

1.  Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option.

Authors:  Franziska Schauer; Norito Ishii; Maja Mockenhaupt; Leena Bruckner-Tuderman; Takashi Hashimoto; Dimitra Kiritsi
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.